Aragon doses first patient in Phase I breast cancer study of ARN-810

4th April 2013 (Last Updated April 4th, 2013 18:30)

Aragon Pharmaceuticals has announced the dosing of the first patient in its Phase I study of ARN-810 in estrogen receptor-positive breast cancer.

Aragon Pharmaceuticals has announced the dosing of the first patient in its Phase I study of ARN-810 in estrogen receptor-positive breast cancer.

The Phase I dose escalation study, which will be conducted at Vanderbilt University, Mass General Hospital and Memorial Sloan-Kettering Cancer Center, will assess the safety and tolerability of ARN-810.

"ARN-810 is an oral selective estrogen receptor degrader (SERD) designed to treat locally advanced or metastatic estrogen receptor-positive breast cancer in post-menopausal women."

ARN-810 is an oral selective estrogen receptor degrader (SERD) designed to treat locally advanced or metastatic estrogen receptor-positive breast cancer in post-menopausal women.

The nonsteroidal agent degrades the receptor by binding to the estrogen receptor, inducing a conformational change.

Aragon Pharmaceuticals CEO Richard Heyman said ARN-810 is the most advanced candidate in its novel SERD programme.

"Today's announcement represents a landmark step for us, as our SERD program originated within Aragon and is wholly-owned," Heyman said.

"We are hopeful that ARN-810's novel approach to breast cancer therapy will prove to be a more effective, sustained treatment option for this important patient population."

The Vanderbilt-Ingram Cancer Center clinical research associate director and breast cancer programme director Dr Carlos Arteaga said; "This drug may become another treatment option for many women with breast cancer."